Inside This Issue: Retinal Disorders
Top News Alerts: Product Updates, Deals & Financings
Company Spotlight: Eos Neuroscience
Subscribe now to access over 45 articles in this issue and 2500 in the archive covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: Is Forest Underpaying for Clinical Data?
Consolidation in the pharma sector continued with Sanofi-Aventis’ acquisition of Genzyme and Forest Laboratories (FRX) bid for Clinical Data (CLDA) (stories, pages 7 and 8). Forest plans to pay at least $1.2 billion, or $30 per share plus $6 per share in contingent value rights for Clinical Data, which recently got approval for their new antidepressant Viibryd. Viibryd is said to have a better sexual dysfunction side effect profile than current antidepressants, but the true profile and prescribing pattern against generic competition will only be apparent post-launch...
Retinal Disorders: A View on Treatments
A variety of treatments exist and are under development for wet AMD (see clinical trial table, page 13). Wet AMD is a large multi-billion market that is largely dominated by Genentech's monoclonal antibody, called Lucentis. The main drawback of Lucentis is its high price and the need for repeated applications. Lucentis pushed aside Macugen (pegaptanib), the first effective intra-ocular treatment developed by Eyetech and approved in 2004. Lucentis and Macugen inhibit vascular endothelial growth factor (VEGF), a growth factor that stimulates blood vessel growth. This article outlines retinal disorders, current treatments and drug and device therapies in development ...
Eos Neuroscience Sets Sights on Optogenic Therapy for Retinal Disorders
Eos Neuroscience was founded in 2007 by Dr. Ed Boyden, an MIT professor and optogenetics pioneer, Dr. Alan Horsager, a visual neuroscientist and Ben Matteo, now CEO, an entrepreneur and former McKinsey consultant. NeuroInsights spoke with Ben Matteo about the company, its vision, its current status and its future goals. Eos' goal is to restore functional sight to patients who are blind due to photoreceptor diseases such as retinitis pigmentosa (RP) or age related macular degeneration (AMD) using optogenetics, a method for introducing light sensitive proteins into cells using gene therapy...
Companies Covered In This Issue Include: Orexigen, Icagen, Chelsea, pSividia, Targacept, AstraZeneca, Forest Labs, Clinical Data, Genzyme, Sanofi-Aventis, Neuralstem, CeNeRx, Teva, Active Biotech, Epicept, Concentric Medical, Amicus, Alkermes, Ceregene, Acura, King, Genentech, Concert Pharma, Naurex, Pacira, Supernus, ReGear, Depomed, Nfocus, Takeda, Kempharm, Shire, BrainStorm CEll Therapeutics, Elan, Biogen Idec, Otonomy, QRxPharma, Merck, AcelRx, Alexion, Orphatec, NeoVista, Novasom, Medtronic, Stemline, Afraxis, Quest Diagnostics, Athena, Acucela, Otsuka, ReVision, Fovea, PanOptica, Ophthotech, Regeneron, MacuCLEAR, Neurotech S/A, Archemix, Optherion, Second Sight, Oraya Therapeutics, VisionCare Opthalmic, NeoVista, Optobionics, IIp Technologies, Retina Implant GMBH, Nano Retina
Subscribe Now:
|
|
